KLK3 and posterior cortical atrophy: Furthermore, and of note, recent clinical studies have suggested that treatment with the bisphosphonate, zoledronic acid, initiated at the time of ADT therapy administration, delayed the time of prostate-specific antigen failure [125,126], which was not observed if zoledronic acid treatment was delayed [127]—underscoring the notion that early intervention against bone loss is inhibitory to osteoclast mediated reactivation of dormant PCa cells.